ESPE Abstracts

Introduction: Disease-modifying agents, such as anti-CD3 monoclonal antibodies, have shown promising outcomes in improving the management of Type 1 Diabetes (T1D). Immunotherapy with teplizumab has delayed the onset of T1D for three years. It is been administered intravenously for 14 days in children and young people (CYP) aged > eight years already in stage 2 (multiple islet autoantibodies, abnormal glucose tolerance, usually pre-symptomatic). This treatme...